OncoMatch/Clinical Trials/NCT01804686
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Is NCT01804686 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies Ibrutinib for chronic lymphocytic leukemia.
Treatment: Ibrutinib — The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been completed according to the parent protocol, are actively receiving treatment with ibrutinib, and who continue to benefit from ibrutinib treatment.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Chronic Lymphocytic Leukemia
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Prior therapy
Must have received: btk inhibitor (ibrutinib) — clinical trial
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Cancer Center · Duarte, California
- University of California San Diego Medical Center · La Jolla, California
- University of California Los Angeles · Los Angeles, California
- St. Joseph Hospital Center for Cancer Prevention and Treatment · Orange, California
- Stanford University Medical Center · Stanford, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT01804686 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received btk inhibitor.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify